Editas Medicine

Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.

Funding reportedLast round: Post ipo equity

BiotechnologyCambridge, United States

What company datasets say Editas Medicine raised

Funding, as reported

Reported in all$932Min dollars

Rounds7

Last roundPost ipo equity

Last round dateJun 2023

Investors listed19

SEC Form D$120M sold, 1 filing, last Aug 2015

From the SEC filings it signed: 4 on the team.

On the board, as filediAlexis BorisyBoris NikolicDouglas ColeKevin Bitterman

Investors who name them

Each firm lists Editas Medicine on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Editas Medicine in front of investors. Or tell us what we have wrong.